Valeant Pharmaceuticals agreed to purchase Solta Medical’s shares at $2.92 per cash share. The deal is expected to close in the first quarter of 2014.
Solta Medical develops energy-based aesthetic medical device systems. Its total revenue in 2012 was $145 million, according to the report.
More Articles on Supply Chain Transactions:
CVS, Cardinal Health Enter Generic Drug Joint Venture
Northeast Purchasing Coalition Moves to Online Contracting
Myco Medical, Novation Enter Private-Label Contract
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
